CHICAGO – Despite all the focus on immuno-oncology, targeted therapy is still alive and well, albeit with a focus on small populations of patients. During a session at the American Association for Cancer Research meeting, principal investigators testing precision medicine therapies highlighted the drugs’ ability to hone in on patients in most need of additional treatments.